| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HAS2 |
| Uniprot No | Q92819 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-552aa |
| 氨基酸序列 | MHCERFLCILRIIGTTLFGVSLLLGITAAYIVGYQFIQTDNYYFSFGLYGAFLASHLIIQSLFAFLEHRKMKKSLETPIKLNKTVALCIAAYQEDPDYLRKCLQSVKRLTYPGIKVVMVIDGNSEDDLYMMDIFSEVMGRDKSATYIWKNNFHEKGPGETDESHKESSQHVTQLVLSNKSICIMQKWGGKREVMYTAFRALGRSVDYVQVCDSDTMLDPASSVEMVKVLEEDPMVGGVGGDVQILNKYDSWISFLSSVRYWMAFNIERACQSYFGCVQCISGPLGMYRNSLLHEFVEDWYNQEFMGNQCSFGDDRHLTNRVLSLGYATKYTARSKCLTETPIEYLRWLNQQTRWSKSYFREWLYNAMWFHKHHLWMTYEAIITGFFPFFLIATVIQLFYRGKIWNILLFLLTVQLVGLIKSSFASCLRGNIVMVFMSLYSVLYMSSLLPAKMFAIATINKAGWGTSGRKTIVVNFIGLIPVSVWFTILLGGVIFTIYKESKRPFSESKQTVLIVGTLLYACYWVMLLTLYVVLINKCGRRKKGQQYDMVLDV |
| 预测分子量 | 63,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HAS2重组蛋白的参考文献示例(注：以下内容为示例性概括，实际文献需通过学术数据库查询)：
1. **标题**：*"Recombinant human hyaluronan synthase 2 (HAS2) expressed in HEK293 cells synthesizes high molecular weight hyaluronan"*
**作者**：Itano N, et al.
**摘要**：研究在HEK293细胞中成功表达重组HAS2蛋白，证实其能高效合成高分子量透明质酸，并揭示其酶活性依赖UDP-葡萄糖的供应。
2. **标题**：*"Post-translational modification of HAS2 regulates hyaluronan synthesis and cell migration in breast cancer cells"*
**作者**：Bourguignon LY, et al.
**摘要**：通过重组HAS2蛋白实验，发现磷酸化修饰可增强其酶活性，促进乳腺癌细胞的透明质酸合成及迁移能力。
3. **标题**：*"Functional characterization of HAS2 variants using a bacterial recombinant expression system"*
**作者**：Pummill PE, et al.
**摘要**：利用大肠杆菌系统表达重组HAS2突变体，发现特定结构域突变导致透明质酸链长改变，为相关遗传病机制提供依据。
4. **标题**：*"Targeting HAS2 in fibrosis: Recombinant HAS2 inhibition reduces collagen deposition in murine models"*
**作者**：Meran S, et al.
**摘要**：通过抑制重组HAS2活性，显著降低实验模型中透明质酸过度积累，缓解纤维化进程，提示其作为治疗靶点的潜力。
---
**提示**：实际文献建议通过PubMed、Web of Science等平台搜索关键词“HAS2 recombinant”“hyaluronan synthase 2 expression”获取最新研究。
Hyaluronan synthase 2 (HAS2) is a key enzyme responsible for synthesizing hyaluronan (HA), a high-molecular-weight glycosaminoglycan critical for maintaining extracellular matrix (ECM) structure and cellular homeostasis. Belonging to the HAS family (HAS1. HAS2. HAS3), HAS2 is a transmembrane protein that catalyzes the elongation of HA chains by alternately adding UDP-glucuronic acid and UDP-N-acetylglucosamine. Unlike other isoforms, HAS2 generates longer HA polymers, which play unique roles in cell signaling, tissue hydration, and mechanical support. Its expression is tightly regulated during embryogenesis, wound healing, and disease processes, including cancer and fibrosis.
Recombinant HAS2 protein, produced via genetic engineering in systems like mammalian cells or bacteria, enables controlled study and application of HA synthesis. Researchers use it to investigate HA’s role in ECM remodeling, inflammation, and cell migration. In biomedicine, recombinant HAS2 has potential in tissue engineering for generating HA-rich scaffolds or modulating HA levels in degenerative conditions. It also holds promise in dermatology for developing HA-based therapies targeting skin aging or hydration.
Dysregulated HAS2 expression is linked to pathological HA accumulation, promoting tumor progression or organ fibrosis. Thus, recombinant HAS2 serves as a tool to explore therapeutic strategies, such as inhibiting HA overproduction or restoring its balance. Recent studies focus on post-translational modifications (e.g., phosphorylation) and regulatory networks (e.g., TGF-β signaling) influencing HAS2 activity. By leveraging recombinant HAS2. scientists aim to decode HA’s dual roles in health and disease, advancing applications from regenerative medicine to targeted cancer therapies.
×
